Is now the time to reconsider risks, benefits, and limitations of estrogen preparations as a treatment for menstrually related migraine?

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi: 10.1177/0333102417738202.
   PubMed Web of Science ®Google Scholar
• Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210. DOI:10.1111/j.1468-2982.2007.01288.x
   PubMed Web of Science ®Google Scholar
• Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87. DOI:10.1016/S1474-4422(16)30293-9.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45(Suppl 1):S3–13.
   PubMed Web of Science ®Google Scholar
• Victor TW, Hu X, Campbell JC, et al. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30(9):1065–1072. DOI:10.1177/0333102409355601
   PubMed Web of Science ®Google Scholar
• Stewart WF, Linet MS, Celentano DD, et al. Age- and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol. 1991;134(10):1111–1120. DOI:10.1093/oxfordjournals.aje.a116014
   PubMed Web of Science ®Google Scholar
• Manzoni GC, Torelli P. Epidemiology of migraine. J Headache Pain. 2003;4(1):S18–22.
   Google Scholar
• Nappi RE, Nappi G. Neuroendocrine aspects of migraine in women. Gynecol Endocrinol. 2012;28(Suppl 1):37–41.
   PubMedGoogle Scholar
• Faubion SS, Batur P, Calhoun AH. Migraine throughout the female reproductive life cycle. Mayo Clin Proc. 2018;93(5):639–645.
   PubMedGoogle Scholar
• Nappi RE, Berga SL. Migraine and reproductive life. Handb Clin Neurol. 2010;97:303–322.
   PubMedGoogle Scholar
• van Casteren DS, Verhagen IE, van der Arend BWH, et al. Comparing perimenstrual and nonperimenstrual migraine attacks using an e-diary. Neurology. 2021;97(17):e1661–1671. DOI:10.1212/WNL.0000000000012723
   PubMed Web of Science ®Google Scholar
• Nappi RE, Sances G, Brundu B, et al. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum Reprod. 2005;20(12):3423–3428. DOI:10.1093/humrep/dei260
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002;42(9):924–929. DOI:10.1046/j.1526-4610.2002.02215.x
   PubMed Web of Science ®Google Scholar
• Ahmad SR, Rosendale N. Sex and gender considerations in episodic migraine. Curr Pain Headache Rep. 2022;26(7):505–516.
   PubMedGoogle Scholar
• Vetvik KG, MacGregor EA. Menstrual migraine: a distinct disorder needing greater recognition. Lancet Neurol. 2021;20(4):304–315.
   PubMed Web of Science ®Google Scholar
• Crawford MJ, Lehman L, Slater S, et al. Menstrual migraine in adolescents. Headache. 2009;49(3):341–347. DOI:10.1111/j.1526-4610.2009.01347.x
   PubMed Web of Science ®Google Scholar
• Vetvik KG, Macgregor EA, Lundqvist C, et al. Prevalence of menstrual migraine: a population-based study. Cephalalgia. 2014;34(4):280–288. DOI:10.1177/0333102413507637
   PubMed Web of Science ®Google Scholar
• Tai MS, Yet SXE, Lim TC, et al. Geographical differences in trigger factors of tension-type headaches and migraines. Curr Pain Headache Rep. 2019;23(2):12.
   PubMedGoogle Scholar
• McGinley JS, Wirth RJ, Pavlovic JM, et al. Between and within-woman differences in the association between menstruation and migraine days. Headache. 2021;61(3):430–437. DOI:10.1111/head.14058
   PubMedGoogle Scholar
• Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24(9):707–716. DOI:10.1111/j.1468-2982.2004.00741.x.
   PubMed Web of Science ®Google Scholar
• Colson N, Fernandez F, Griffiths L. Genetics of menstrual migraine: the molecular evidence. Curr Pain Headache Rep. 2010;14(5):389–395.
   PubMedGoogle Scholar
• Labruijere S, Stolk L, Verbiest M, et al. Methylation of migraine-related genes in different tissues of the rat. PLoS ONE. 2014;9(3):e87616. DOI:10.1371/journal.pone.0087616
   PubMedGoogle Scholar
• Nappi RE, Tiranini L, Sacco S, et al. Role of estrogens in menstrual migraine. Cells. 2022;11(8):1355. DOI:10.3390/cells11081355
   PubMedGoogle Scholar
• Krause DN, Warfvinge K, Haanes KA, et al. Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP. Nat Rev Neurol. 2021;17(10):621–633. DOI:10.1038/s41582-021-00544-2.
   PubMed Web of Science ®Google Scholar
• Brandes JL. The influence of estrogen on migraine: a systematic review. JAMA. 2006 19;295(15):1824–1830. DOI:10.1001/jama.295.15.1824.
   PubMed Web of Science ®Google Scholar
• Warfvinge K, Krause DN, Maddahi A, et al. Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects. J Headache Pain. 2020;21(1):131. DOI:10.1186/s10194-020-01197-0
   PubMed Web of Science ®Google Scholar
• Craft RM. Modulation of pain by estrogens. Pain. 2007;Suppl 132(Supplement 1):S3–12.
   Google Scholar
• Tassorelli C, Sandrini G, Cecchini AP, et al. Changes in nociceptive flexion reflex threshold across the menstrual cycle in healthy women. Psychosom Med. 2002;64(4):621–626. DOI:10.1097/00006842-200207000-00012
   PubMedGoogle Scholar
• Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015;21(6):762–778.
   PubMed Web of Science ®Google Scholar
• Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol. 2014;27(3):315–324.
   PubMed Web of Science ®Google Scholar
• Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis–part 2. Headache. 2006;46(3):365–386.
   PubMed Web of Science ®Google Scholar
• Reddy N, Desai MN, Schoenbrunner A, et al. The complex relationship between estrogen and migraines: a scoping review. Syst Rev. 2021;10(1):72. DOI:10.1186/s13643-021-01618-4
   PubMed Web of Science ®Google Scholar
• Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972;22(4):355–365.
   PubMed Web of Science ®Google Scholar
• Somerville BW. Estrogen-withdrawal migraine. II. Attempted prophylaxis by continuous estradiol administration. Neurology. 1975;25(3):245–250.
   PubMedGoogle Scholar
• MacGregor EA. Perimenopausal migraine in women with vasomotor symptoms. Maturitas. 2012;71(1):79–82.
   PubMedGoogle Scholar
• Martin V, Wernke S, Mandell K, et al. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache. 2003;43(4):309–321. DOI:10.1046/j.1526-4610.2003.03065.x
   PubMedGoogle Scholar
• Pavlović JM, Allshouse AA, Santoro NF, et al. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology. 2016;87(1):49–56. DOI:10.1212/WNL.0000000000002798
   PubMed Web of Science ®Google Scholar
• MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3(6):354–361.
   PubMed Web of Science ®Google Scholar
• Martin VT, Behbehani M, Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part I. Headache. 2006;46(1):3–23.
   PubMed Web of Science ®Google Scholar
• Fioroni L, Martignoni E, Facchinetti F. Changes of neuroendocrine axes in patients with menstrual migraine. Cephalalgia. 1995;15(4):297–300.
   PubMedGoogle Scholar
• Nappi RE, Sances G, Brundu B, et al. Neuroendocrine response to the serotonin agonist M-chlorophenylpiperazine in women with menstrual status migrainosus. Neuroendocrinology. 2003;78(1):52–60. DOI:10.1159/000071706
   PubMedGoogle Scholar
• Facchinetti F, Allais G, Nappi RE, et al. Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study. Gynecol Endocrinol. 2010;26(10):773–779. DOI:10.3109/09513590.2010.487607
   PubMed Web of Science ®Google Scholar
• De Icco R, Cucinella L, De Paoli I, et al. Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. J Headache Pain. 2016;17(1):70. DOI:10.1186/s10194-016-0661-6.
   PubMedGoogle Scholar
• Ferrari MD, Klever RR, Terwindt GM, et al. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol. 2015;14(1):65–80. DOI:10.1016/S1474-4422(14)70220-0
   PubMed Web of Science ®Google Scholar
• González SL, Meyer L, Raggio MC, et al. Allopregnanolone and progesterone in experimental neuropathic pain: former and new insights with a translational perspective. Cell Mol Neurobiol. 2019;39(4):523–537. DOI:10.1007/s10571-018-0618-1
   PubMedGoogle Scholar
• Rustichelli C, Bellei E, Bergamini S, et al. Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: a cross-sectional study. Cephalalgia. 2020;40(12):1355–1362. DOI:10.1177/0333102420937742
   PubMedGoogle Scholar
• Messlinger K, Russo AF. Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia. 2019;39(13):1661–1674.
   PubMed Web of Science ®Google Scholar
• Zhang X, Levy D, Kainz V, et al. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol. 2011;69(5):855–865. DOI:10.1002/ana.22329
   PubMed Web of Science ®Google Scholar
• Labastida-Ramírez A, Rubio-Beltrán E, Villalón CM, et al. Gender aspects of CGRP in migraine. Cephalalgia. 2019;39(3):435–444. DOI:10.1177/0333102417739584
   PubMed Web of Science ®Google Scholar
• Edvinsson JC, Reducha PV, Sheykhzade M, et al. Neurokinins and their receptors in the rat trigeminal system: differential localization and release with implications for migraine pain. Mol Pain. 2021;17:17448069211059400.
   Google Scholar
• Cetinkaya A, Kilinc E, Camsari C, et al. Effects of estrogen and progesterone on the neurogenic inflammatory neuropeptides: implications for gender differences in migraine. Exp Brain Res. 2020;238(11):2625–2639. DOI:10.1007/s00221-020-05923-7
   PubMed Web of Science ®Google Scholar
• Delaruelle Z, Ivanova TA, Khan S, et al. European Headache Federation School of Advanced Studies (EHF-SAS). Male and female sex hormones in primary headaches. J Headache Pain. 2018;19(1):117. DOI:10.1186/s10194-018-0922-7
   PubMed Web of Science ®Google Scholar
• Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999;103(3):401–406. DOI:10.1172/JCI5347
   PubMed Web of Science ®Google Scholar
• Antonova M, Wienecke T, Olesen J, et al. Prostaglandins in migraine: update. Curr Opin Neurol. 2013;26(3):269–275. DOI:10.1097/WCO.0b013e328360864b
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Tognoloni M, Russo S, et al. Variations in the platelet arginine/nitric oxide pathway during the ovarian cycle in females affected by menstrual migraine. Cephalalgia. 1996;16(7):468–475. DOI:10.1046/j.1468-2982.1996.1607468.x
   PubMedGoogle Scholar
• Durham PL, Vause CV, Derosier F, et al. Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache. 2010;50(5):844–851. DOI:10.1111/j.1526-4610.2010.01657.x
   PubMed Web of Science ®Google Scholar
• Ashina M, Hansen JM, Á Dunga BO, et al. Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol. 2017;13(12):713–724. DOI:10.1038/nrneurol.2017.137
   PubMed Web of Science ®Google Scholar
• Critchley HOD, Maybin JA, Armstrong GM, et al. Physiology of the endometrium and regulation of menstruation. Physiol Rev. 2020;100(3):1149–1179. DOI:10.1152/physrev.00031.2019
   PubMed Web of Science ®Google Scholar
• Yamanaka G, Suzuki S, Morishita N, et al. Role of neuroinflammation and blood-brain barrier permutability on migraine. Int J Mol Sci. 2021;22(16):8929. DOI:10.3390/ijms22168929
   PubMedGoogle Scholar
• Mannix LK. Menstrual-related pain conditions: dysmenorrhea and migraine. J Womens Health (Larchmt). 2008;17(5):879–891.
   PubMed Web of Science ®Google Scholar
• Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol. 2009;114(1):106–113. DOI:10.1097/AOG.0b013e3181a98e4d.
   PubMed Web of Science ®Google Scholar
• Buse DC, Reed ML, Fanning KM, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2020;21(1):23. DOI:10.1186/s10194-020-1084-y
   PubMed Web of Science ®Google Scholar
• Lamvu G, Carrillo J, Ouyang C, et al. Chronic pelvic pain in women: a review. JAMA. 2021;325(23):2381–2391. DOI:10.1001/jama.2021.2631
   PubMed Web of Science ®Google Scholar
• Affaitati G, Costantini R, Tana C, et al. Co-occurrence of pain syndromes. J Neural Transm (Vienna). 2020;127(4):625–646. DOI:10.1007/s00702-019-02107-8
   PubMed Web of Science ®Google Scholar
• Ferries-Rowe E, Corey E, Js A. Primary dysmenorrhea: diagnosis and therapy. Obstet Gynecol. 2020;136(5):1047–1058.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Viganò P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–275. DOI:10.1038/nrendo.2013.255
   PubMed Web of Science ®Google Scholar
• Chapron C, Vannuccini S, Santulli P, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum Reprod Update. 2020;26(3):392–411. DOI:10.1093/humupd/dmz049
   PubMed Web of Science ®Google Scholar
• Tietjen GE, Conway A, Utley C, et al. Migraine is associated with menorrhagia and endometriosis. Headache. 2006;46(3):422–428. DOI:10.1111/j.1526-4610.2006.00290.x
   PubMed Web of Science ®Google Scholar
• Tietjen GE, Bushnell CD, Herial NA, et al. Endometriosis is associated with prevalence of comorbid conditions in migraine. Headache. 2007;47(7):1069–1078. DOI:10.1111/j.1526-4610.2007.00784.x
   PubMed Web of Science ®Google Scholar
• McNamara HC, Frawley HC, Donoghue JF, et al. Peripheral, central, and cross sensitization in endometriosis-associated pain and comorbid pain syndromes. Front Reprod Health. 2021;3:729642.
   PubMedGoogle Scholar
• Raffaelli B, Overeem LH, Mecklenburg J, et al. Plasma calcitonin gene-related peptide (CGRP) in migraine and endometriosis during the menstrual cycle. Ann Clin Transl Neurol. 2021;8(6):1251–1259. DOI:10.1002/acn3.51360
   PubMedGoogle Scholar
• Van der Vaart JF, Merki-Feld GS. Sex hormone-related polymorphisms in endometriosis and migraine: a narrative review. Women's Health (Lond). 2022;18:17455057221111315.
   Google Scholar
• Martin VT, Allen JR, Houle TT, et al. Ovarian hormones, age and pubertal development and their association with days of headache onset in girls with migraine: an observational cohort study. Cephalalgia. 2018;38(4):707–717. DOI:10.1177/0333102417706980
   PubMedGoogle Scholar
• Maleki N, Kurth T, Field AE. Age at menarche and risk of developing migraine or non-migraine headaches by young adulthood: a prospective cohort study. Cephalalgia. 2017;37(13):1257–1263.
   PubMed Web of Science ®Google Scholar
• Parazzini F, Esposito G, Tozzi L, et al. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol. 2017;209:3–7.
   PubMed Web of Science ®Google Scholar
• Miller JA, Missmer SA, Vitonis AF, et al. Prevalence of migraines in adolescents with endometriosis. Fertil Steril. 2018;109(4):685–690. DOI:10.1016/j.fertnstert.2017.12.016
   PubMed Web of Science ®Google Scholar
• Karp BI, Sinaii N, Nieman LK, et al. Migraine in women with chronic pelvic pain with and without endometriosis. Fertil Steril. 2011;95(3):895–899. DOI:10.1016/j.fertnstert.2010.11.037
   PubMed Web of Science ®Google Scholar
• Evans SF, Brooks TA, Esterman AJ, et al. The comorbidities of dysmenorrhea: a clinical survey comparing symptom profile in women with and without endometriosis. J Pain Res. 2018;11:3181–3194.
   PubMed Web of Science ®Google Scholar
• Borsook D, Erpelding N, Lebel A, et al. Sex and the migraine brain. Neurobiol Dis. 2014;68:200–214.
   PubMed Web of Science ®Google Scholar
• Gür-Özmen S, Karahan-Özcan R. Iron deficiency anemia is associated with menstrual migraine: a case-control study. Pain Med. 2016;17(3):596–605.
   PubMedGoogle Scholar
• Calhoun AH, Gill N. Presenting a new, non-hormonally mediated cyclic headache in women: end-menstrual migraine. Headache. 2017;57(1):17–20.
   PubMedGoogle Scholar
• Vetvik KG, MacGregor EA, Lundqvist C, et al. Contraceptive-induced amenorrhoea leads to reduced migraine frequency in women with menstrual migraine without aura. J Headache Pain. 2014;15(1):30. DOI:10.1186/1129-2377-15-30
   PubMedGoogle Scholar
• Maguire K, Westhoff C. The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet Gynecol. 2011;205(4 Suppl):S4–8.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000;27(4):705–721.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018;110(1):137–152.e1.
   PubMed Web of Science ®Google Scholar
• Calhoun AH. Menstrual migraine: update on pathophysiology and approach to therapy and management. Curr Treat Options Neurol. 2012;14(1):1–14.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kaunitz AM, Bitzer J. Extended regimen combined oral contraception: a review of evolving concepts and acceptance by women and clinicians. Eur J Contracept Reprod Health Care. 2016;21(2):106–115.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Sandor PS, Nappi RE, et al. Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study. Acta Neurol Belg. 2022;122(2):401–409. DOI:10.1007/s13760-021-01677-3
   PubMedGoogle Scholar
• Mannix LK, Calhoun AH. Menstrual Migraine. Curr Treat Options Neurol. 2004;6(6):489–498.
   PubMedGoogle Scholar
• Tassorelli C, Greco R, Allena M, et al. Transdermal hormonal therapy in perimenstrual migraine: why, when and how? Curr Pain Headache Rep. 2012;16(5):467–473. DOI:10.1007/s11916-012-0293-8
   PubMedGoogle Scholar
• Allais G, Chiarle G, Sinigaglia S, et al. Treating migraine with contraceptives. Neurol Sci. 2017;38(Suppl 1):85–89. DOI:10.1007/s10072-017-2906-9
   PubMed Web of Science ®Google Scholar
• Calhoun A, Ford S. Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache. 2008;48(8):1186–1193. DOI:10.1111/j.1526-4610.2008.01176.x.
   PubMed Web of Science ®Google Scholar
• Schroeder RA, Brandes J, Buse DC, et al. Sex and gender differences in migraine-evaluating knowledge gaps. J Womens Health (Larchmt). 2018;27(8):965–973. DOI:10.1089/jwh.2018.7274
   PubMedGoogle Scholar
• MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reprod Health. 2018;24(1):11–18.
   PubMedGoogle Scholar
• Warhurst S, Rofe CJ, Brew BJ, et al. Effectiveness of the progestin-only pill for migraine treatment in women: a systematic review and meta-analysis. Cephalalgia. 2018;38(4):754–764. DOI:10.1177/0333102417710636
   PubMed Web of Science ®Google Scholar
• London A, Jensen JT. Rationale for eliminating the hormone-free interval in modern oral contraceptives. Int J Gynaecol Obstet. 2016 Jul;134(1):8–12.
   PubMedGoogle Scholar
• MacGregor EA, Guillebaud J. The 7-day contraceptive hormone-free interval should be consigned to history. BMJ Sex Reprod Health. 2018 Jun 26;44(3):214–220.
   Google Scholar
• Ornello R, Canonico M, Merki-Feld GS, et al. Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. Expert Rev Neurother. 2020;20(4):313–317. DOI:10.1080/14737175.2020.1730816
   PubMed Web of Science ®Google Scholar
• Tietjen GE, Maly EF. Migraine and ischemic stroke in women. A narrative review. Headache. 2020;60(5):843–863.
   PubMedGoogle Scholar
• Sheikh HU, Pavlovic J, Loder E, et al. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review. Headache. 2018;58(1):5–21. DOI:10.1111/head.13229
   PubMedGoogle Scholar
• Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: a bench to bedside review. Thromb Res. 2020;192:40–51.
   PubMed Web of Science ®Google Scholar
• Øie LR, Kurth T, Gulati S, et al. Migraine and risk of stroke. J Neurol Neurosurg Psychiatry. 2020;91(6):593–604.
   PubMed Web of Science ®Google Scholar
• Sacco S, Ornello R, Ripa P, et al. Migraine and hemorrhagic stroke: a meta-analysis. Stroke. 2013 Nov;44(11):3032–3038.
   PubMed Web of Science ®Google Scholar
• Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology. 2005;64(6):1020–1026. DOI:10.1212/01.WNL.0000154528.21485.3A.
   PubMed Web of Science ®Google Scholar
• Sacco S, Merki-Feld GS, Ægidius KL, et al. European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18(1):108. DOI:10.1186/s10194-017-0815-1.
   PubMed Web of Science ®Google Scholar
• Martin VT, Lipton RB. Epidemiology and biology of menstrual migraine. Headache. 2008;48(Suppl 3):S124–30.
   PubMedGoogle Scholar
• Nappi RE, Merki-Feld GS, Terreno E, et al. Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? J Headache Pain. 2013;14(1):66. DOI:10.1186/1129-2377-14-66
   PubMed Web of Science ®Google Scholar
• Voedisch AJ, Hindiyeh N. Combined hormonal contraception and migraine: are we being too strict? Curr Opin Obstet Gynecol. 2019;31(6):452–458.
   PubMedGoogle Scholar
• Calhoun AH, Batur P. Combined hormonal contraceptives and migraine: an update on the evidence. Cleve Clin J Med. 2017;84(8):631–638.
   PubMedGoogle Scholar
• Donaghy M, European Collaborators of The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry. 2002;73(6):747–750. DOI:10.1136/jnnp.73.6.747.
   PubMed Web of Science ®Google Scholar
• MacGregor EA. Contraception and headache. Headache. 2013;53(2):247–276.
   PubMed Web of Science ®Google Scholar
• Bentivegna E, Luciani M, Scarso F, et al. Hormonal therapies in migraine management: current perspectives on patient selection and risk management. Expert Rev Neurother. 2021;21(12):1347–1355. DOI:10.1080/14737175.2021.2003706
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Trémollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. 2012;28(5):400–408.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Bastianelli C, Farris M. Hormonal contraception: present and future. Drugs Today. 2008;44(12):905.
   PubMedGoogle Scholar
• Shulman LP. The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives. Am J Clin Exp Obstet Gynecol. 2011;205(4, Supplement):S9–13.
   Google Scholar
• Royer PA, Jones KP. Progestins for contraception: modern delivery systems and novel formulations. Clin Obstet Gynecol. 2014;57(4):644–658.
   PubMedGoogle Scholar
• Morimont L, Haguet H, Dogné JM, et al. Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol. 2021;12:769187.
   PubMed Web of Science ®Google Scholar
• Roach REJ, Helmerhorst FM, Lijfering WM, et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;2015(8):CD011054.
   PubMedGoogle Scholar
• Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016;94(6):678–700. DOI:10.1016/j.contraception.2016.04.014
   PubMed Web of Science ®Google Scholar
• Tepper NK, Whiteman MK, Zapata LB, et al. Safety of hormonal contraceptives among women with migraine: a systematic review. Contraception. 2016;94(6):630–640. DOI:10.1016/j.contraception.2016.04.016
   PubMed Web of Science ®Google Scholar
• Voedisch AJ, Fok WK. Oestrogen component of COCs: have we finally found a replacement for ethinyl estradiol? Curr Opin Obstet Gynecol. 2021;33(6):433–439.
   PubMed Web of Science ®Google Scholar
• Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94(4):328–339.
   PubMed Web of Science ®Google Scholar
• Reed S, Koro C, DiBello J, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care. 2021;26(6):439–446. DOI:10.1080/13625187.2021.1987410
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Fidecicchi T, Montt Guevara MM, et al. Estetrol: a new choice for contraception. J Clin Med. 2021;10(23):5625. DOI:10.3390/jcm10235625
   PubMed Web of Science ®Google Scholar
• Ryan RE. A controlled study of the effect of oral contraceptives on migraine. Headache. 1978;17(6):250–252.
   PubMedGoogle Scholar
• Granella F, Sances G, Zanferrari C, et al. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33(7):385–389. DOI:10.1111/j.1526-4610.1993.hed3307385.x
   PubMed Web of Science ®Google Scholar
• Granella F, Sances G, Pucci E, et al. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000;20(8):701–707. DOI:10.1046/j.1468-2982.2000.00112.x
   PubMedGoogle Scholar
• Loder EW, Buse DC, Golub JR. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache. 2005 Mar;45(3):224–231.
   PubMedGoogle Scholar
• Machado RB, Pereira AP, Coelho GP, et al. Epidemiological and clinical aspects of migraine in users of combined oral contraceptives. Contraception. 2010 Mar;81(3):202–208.
   PubMedGoogle Scholar
• Gallo MF, Nanda K, Grimes DA, et al. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;2013(8):CD003989. DOI:10.1002/14651858.CD003989.pub5
   PubMedGoogle Scholar
• van den Heuvel MW, van Bragt AJ, Alnabawy AK, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168–174. DOI:10.1016/j.contraception.2005.03.005
   PubMed Web of Science ®Google Scholar
• Calhoun A, Ford S, Pruitt A. The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series. Headache. 2012;52(8):1246–1253.
   PubMedGoogle Scholar
• De Leo V, Scolaro V, Musacchio MC, et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011;96(4):917–920. DOI:10.1016/j.fertnstert.2011.07.1089
   PubMed Web of Science ®Google Scholar
• Sulak P, Willis S, Kuehl T, et al. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47(1):27–37. DOI:10.1111/j.1526-4610.2007.00650.x
   PubMed Web of Science ®Google Scholar
• Coffee AL, Sulak PJ, Hill AJ, et al. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines. J Womens Health (Larchmt). 2014 Apr;23(4):310–317.
   PubMedGoogle Scholar
• Macgregor EA, Hackshaw A. Prevention of migraine in the pill-free interval of combined oral contraceptives: a double-blind, placebo-controlled pilot study using natural oestrogen supplements. J Fam Plann Reprod Health Care. 2002;28(1):27–31.
   PubMedGoogle Scholar
• Calhoun AH. A novel specific prophylaxis for menstrual-associated migraine. South Med J. 2004;97(9):819–822.
   PubMedGoogle Scholar
• Macìas G, Merki-Feld GS, Parke S, et al. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J Obstet Gynaecol. 2013;33(6):591–596. DOI:10.3109/01443615.2013.800851
   PubMedGoogle Scholar
• Nappi RE, Terreno E, Sances G, et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013;88(3):369–375. DOI:10.1016/j.contraception.2013.02.001.
   PubMed Web of Science ®Google Scholar
• Graziottin A. The shorter, the better: a review of the evidence for a shorter contraceptive hormone-free interval. Eur J Contracept Reprod Health Care. 2016;21(2):93–105.
   PubMed Web of Science ®Google Scholar
• European Headache Federation (EHF), the European Society of Contraception and Reproductive Health (ESCRH); Sacco S, Merki-Feld GS, AEgidius Kl, et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018;19(1):76.
   PubMed Web of Science ®Google Scholar
• Stevenson JC. Type and route of estrogen administration. Climacteric. 2009;12 Suppl 1:86–90.
   PubMedGoogle Scholar
• MacGregor EA, Frith A, Ellis J, et al. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006;67(12):2159–2163. DOI:10.1212/01.wnl.0000249114.52802.55
   PubMedGoogle Scholar
• de Lignières B, Vincens M, Mauvais-Jarvis P, et al. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J. 1986;293(6561):1540. Clin Res Ed. 10.1136/bmj.293.6561.1540
   PubMedGoogle Scholar
• Dennerstein L, Morse C, Burrows G, et al. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol. 1988;2(2):113–120. DOI:10.3109/09513598809023619
   PubMed Web of Science ®Google Scholar
• Smits MG, van der Meer YG, Pfeil JP, et al. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache. 1994;34(2):103–106. DOI:10.1111/j.1526-4610.1994.hed3402103.x
   PubMedGoogle Scholar
• Almén-Christensson A, Hammar M, Lindh-Åstrand L, et al. Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study. Fertil Steril. 2011;96(2):498–500.e1. DOI:10.1016/j.fertnstert.2011.05.089
   PubMed Web of Science ®Google Scholar
• Guidotti M, Mauri M, Barrilà C, et al. Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. J Headache Pain. 2007;8(5):283–288.
   PubMedGoogle Scholar
• Järvinen A, Nykänen S, Paasiniemi L. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas. 1999;32(2):103–113.
   PubMed Web of Science ®Google Scholar
• Canonico M, Carcaillon L, Plu-Bureau G, et al. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke. 2016;47(7):1734–1741. DOI:10.1161/STROKEAHA.116.013052
   PubMed Web of Science ®Google Scholar